Bangkok, Market for Alternative Investment (mai) will list
The Klinique Medical Clinic pcl, an aesthetics, plastic surgery, and wellness
center, on November 7, under the ticker symbol “KLINIQ”. The company has a
market capitalization at its initial public offering (IPO) of THB 5.39 billion
(approx. USD 141.77 million).
mai President Prapan Charoenprawatt said that KLINIQ would list and start
trading on mai in the Services industry group.
KLINIQ provides services on aesthetic dermatology, plastic surgery, and advanced
preventive and holistic health rehabilitation in compliance with medical
principles, consisting of skin disease treatment, cosmetic skin treatment,
weight loss, body contouring, surgery, wellness and regeneration by a team of
medical specialists in aesthetic and cosmetic surgery certified by well-known
institutions in Thailand, the United States and the United Kingdom with
experience in providing medical examination & treatment services in skin
diseases and surgery equipped with advanced technology under the brand “The
Klinique”. As of June 30, 2022, the company has 39 branches in leading
department stores, covering 15 provinces, all over five regions of Thailand. The
39 branches comprise 35 medical clinics, one surgical center at Siam Square in
downtown Bangkok and three nail salons.
KLINIQ has a paid-up capital of THB 110 million, consisting of 160 million
existing ordinary shares and 60 million newly issued shares, with a par value of
THB 0.50 each. It offered up to 6 million newly issued shares to the company’s
directors, executives and employees, not over 9 million shares to the company’s
patrons, and at least 45 million shares to institutional investors and
individuals at the underwriters’ discretion, during October 28, 31, and November
1, at THB 24.50 each, for a total of THB 1.47 billion. The IPO price was
equivalent to price-to-earnings ratio (P/E ratio) of 31.78 times. The earnings
per share is equal to THB 0.77, which was calculated from the company’s net
profit of THB 169.60 million in the past four quarters (from July 1, 2021 to
June 30, 2022), divided by fully diluted shares. Daol Securities (Thailand) pcl
is the financial advisor and lead underwriter.
KLINIQ’s Chief Executive Officer Apiruj Thongwattana, M.D. said that the company
prioritizes safety and customer satisfaction, and always provides services with
innovative and state-of-the-art medical equipment. It is a must to have the
innovations and medical devices accredited and audited by the United States Food
and Drug Administration (US FDA) and Thailand’s FDA, and tested by the
company’s experienced medical team. The company has recorded continuous growth
based on service enhancement and marketing tools to create awareness of ‘The
Klinique’ brand. The fund raised will be used to expand business, purchase
additional medical equipment, expand surgery center, develop IT systems &
customer database, and as working capital.
KLINIQ’s three major shareholders after the IPO are Thongwattana group (52.35
percent), Ekachai Medical Care pcl (7.27 percent), and Rattapol Kittichaitrakul
(7.16 percent). The company’s dividend policy is to pay no less than 40 percent
of net profit from the company’s separate financial statements after corporate
income tax, and legal and other reserves.
Source: The Stock Exchange of Thailand